Does the devil facial tumour produce immunosuppressive cytokines as an immune evasion strategy?

Veterinary Immunology and Immunopathology

Volumn 153, Issue 1-2, 2013, Pages 159-164

  Morris, Katrina ^a   Belov, Katherine ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cytokine; DFTD; Sarcophilus harrisii; Tasmanian devil

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A;

ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DEVIL FACIAL TUMOUR DISEASE; FACE CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE EVASION; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SARCOPHILUS HARRISII; UPREGULATION; ANIMAL; ANIMAL DISEASE; BIOSYNTHESIS; FACE TUMOR; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MARSUPIAL; TUMOR ESCAPE;

SARCOPHILUS HARRISII;

ANIMALS; CYTOKINES; FACIAL NEOPLASMS; FEMALE; IMMUNE TOLERANCE; MALE; MARSUPIALIA; TUMOR ESCAPE;

EID: 84884714151     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2013.02.008     Document Type: Article

References (36)

1. Algarra I., Garcia-Lora A., Ruiz-Cabello T.C.F., Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 2004, 53:904-910.
2. DPIPWE Save The Tasmanian Devil Program: 2010/11 Annual Program Report 2012, Department of Primary Industries, Parks, Water and Environment, Tasmania, viewed May 2012.
3. Enk A.H., Angeloni V.L., Due M.C., Katz S.I. Inhibition of Langerhans cell antigenpresenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol. 1993, 151:2390-2398.
4. Halak B.K., Maguire H.C., Lattime E.C. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 1999, 59:911-917.
5. Higgins D.A. Observations on the canine transmissible venereal tumour as seen in the Bahamas. Vet. Rec. 1996, 79:67-71.
6. Hsiao Y.W., Liao K.W., Hung S.W., Chu R.M. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J. Immunol. 2004, 172:1508-1514.
7. IUCN IUfCoN Red List of Threatened Species. Version 3.1 2011, IUCN, Gland, Switzerland, Available from, (accessed January 2011). http://www.iucnredlist.org/.
8. Johnson B.F., Clay T.M., Hobeika A.C., Lyerly H.K., Morse M.A. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin. Biol. Ther. 2007, 7:449-460.
9. Jones M.E., Jarman P.J., Lees C.M., Hesterman H., Hamede R.K., Mooney N.J., Mann D., Pukk C.E., Bergfeld J., McCallum H. Conservation management of Tasmanian devils in the context of an emerging, extinction-threatening disease: devil facial tumor disease. EcoHealth 2007, 4:326-337.
10. Kaminska B., Wesolowska A., Danilkiewicz M. TGF beta signalling and its role in tumour pathogenesis. Acta Biochim. Pol. 2005, 52:329-337.
11. Kreiss A., Obendorf D.L., Hemsley S., Canfield P.J., Woods G.M. A histological and immunohistochemical analysis of lymphoid tissues of the Tasmanian devil. Anat. Rec. 2009, 292:611-620.
12. Kreiss A., Cheng Y., Kimble F., Wells B., Donovan S., Belov K., Woods G. Allorecognition in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species with limited genetic diversity. PLoS ONE 2011, 6:e22402.
13. Kruger-Krasagakes S., Krasagakis K., Garbe C., Schmitt E., Huls C., Blankenstein T., Diamantstein T. Expression of interleukin 10 in human melanoma. Br. J. Cancer 1994, 70:1182-1185.
14. Kusmartsev S., Gabrilovich D.I. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metast. Rev. 2006, 25:323-331.
15. Loh R., Bergfeld J., Hayes D., O'Hara A., Pyecroft S., Raidal S., Sharpe R. The pathology of Devil Facial Tumour Disease (DFTD) in Tasmanian devils (Sarcophilus harrisii). Vet. Pathol. 2006, 43:890-895.
16. Loh R., Hayes D., Mahjoor A., O'Hara A., Pyecroft S., Radial S. The immunohistochemical characterization of Devil Facial Tumor Disease (DFTD) in the Tasmanian devil (Sarcophilus harrisii). Vet. Pathol. 2006, 43:896-903.
17. Los M., Roodhart J.M., Voest E.E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007, 12:250-443.
18. Löttrich M., Mawrin C., Chamaon K., Kirches E., Dietzmann K., Freigang B. Expression of transforming growth factor-β receptor type 1 and type 2 in human sporadic vestibular Schwannoma. Pathol. Res. Pract. 2007, 203:245-249.
19. Masui T., Hosotani R., Doi R., Miyamoto Y., Tsuji S., Nakajima S., Kobayashi H., Koizumi M., Toyoda E., Tulachan S.S., Imamura M. Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction. Anticancer Res. 2002, 22:4093-4100.
20. McCallum H., Tompkins D.M., Jones M.E., Lachish S., Marvenek S., Lazenby B., Hocking G.J., Wiersma J., Hawkins C. Distribution and impacts of Tasmanian Devil Facial Tumour Disease. EcoHealth 2007, 4:318-325.
21. Murchison E.P., Tovar C., Hsu A., Bender H.S., Kheradpour P., Rebbeck C.A., Obendorf D., Conlan C., Bahlo M., Blizzard C.A., Pyecroft S., Kreiss A., Kellis M., Stark A., Harkins T.T., Graves J.A.M., Woods G.M., Hannon G.J., Papenfuss A.T. The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer. Science 2010, 327:84-87.
22. Natali P.G., Nicotra M.R., Bigotti A., Venturo I., Marcenaro L., Giacomini P., Russo C. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:6719-6723.
23. Pasche B. Role of transforming growth factor β in cancer. J. Cell. Physiol. 2001, 186:153.
24. Pearse A.M., Swift K. Transmission of devil facial-tumour disease. Nature 2006, 439:549.
25. Plotkin S.R., Stemmer-Rachamimov A.O., Barker F.G., 2nd, Halpin C., Padera T.P., Tyrrell A., Sorensen A.G., Jain R.K., di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N. Engl. J. Med. 2009, 361:358-367.
26. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007, 25:267-296.
27. Sharma S.M., Lin Y., Gardner B., Miller P.W., Kronenberg M., Dubinett S.M. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol. 1999, 163:5020-5028.
28. Siddle H., Kriess A., Eldridge M., Noonan E., Clarke C., Pyecroft S., Woods G., Belov K. Transmission of a fatal clonal tumour by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16221-16226.
29. Spaner D.E. Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells. J. Leukoc. Biol. 2004, 76:338-351.
30. Steinbrink K., Jonuleit H., Muller G., Schuler G., Knop J., Enk A.H. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999, 93:1634-1642.
31. Toi M., Kondo S., Suzuki H., Yamamoto Y., Inada K., Imazawa T., Taniguchi T., Tominaga T. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996, 77:1101-1106.
32. Uesaka T., Shono T., Suzuki S.So., Nakamizo A., Niiro H., Mizoguchi M., Iwaki T., Sasaki T. Expression of VEGF and its receptor genes in intracranial schwannomas. J. Neurooncol. 2007, 83:259-266.
33. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., Hsieh C.Y. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527.
34. Woods G.M., Kreiss A., Belov K., Siddle H.V., Obendorf D.L., Muller H.K. The immune response of the Tasmanian devil (Sarcophilus harrisii) and Devil Facial Tumour Disease. EcoHealth 2007, 4:338-345.
35. Yang T.J. Immunobiology of a spontaneously regressive tumor, the canine transmissible venereal sarcoma. Anticancer Res. 1988, 8:93-95.
36. Yang T.J., Chandler J.P., Dunne-Anway S. Growth stage dependent expression of MHC antigens on the canine transmissible venereal sarcoma. Br. J. Cancer 1987, 55:131-134.